The Weekly Roundup: March 18-22

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Poster Presentations Demonstrate Efficacy of Deuruxolitinib in Patients With Moderate to Severe Alopecia Areata

The data suggests that the medication, which targets specific cellular pathways, promotes hair regrowth in AA with minimal adverse effects.

Reviewing Coverage of COVID-19- Related Research in Dermatology From the Past Year

It has been 4 years since the COVID-19 pandemic began. In the time since, there has been plentiful research regarding its implications in dermatology.

FDA Accepts Journey Medical’s NDA for DFD-29 for Rosacea

The anticipated PDUFA date is November 4, 2024.

Advocating for Mohs Surgery in Prison Populations

From our March cover feature: Vulnerable populations such as the prison population should have access to Mohs surgery to prevent the increased risk of morbidity and mortality from skin cancer.

Breaking Down Benzene Testing Methods of Benzoyl Peroxide Products

On March 6, 2024, Valisure, an independent testing laboratory, found high levels of benzene when BPO products were incubated at 37°C, 50°C, and 70°C.

Connecting COVID-19 Research to Impact on Patients With Atopic Dermatitis

Two recent studies delve into outcomes of pediatric populations with atopic conditions and an overview of patient outcomes utilizing a Mendelian randomization analysis.

Gender Disparities in Vitiligo: Psychological Effects and QoL

The social and psychological effects of vitiligo, particularly concerning gender disparities, have come to the forefront in recent literature.

FDA Accepts Citius's Resubmitted BLA for Denileukin Diftitox for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

The FDA has assigned a Prescription Drug User Fee Act target action date for August 13.

FDA Approves Boehringer Ingelheim's Spesolimab-sbzo For Adults and Children With Generalized Pustular Psoriasis

The expanded approval of Spevigo follows the Chinese National Medical Products Administration’s approval for the injection for the reduction of occurrence of GPP.

Robert Den, MD: Exploring the Potential of Alpha DaRT in Skin Cancer

Den, the chief medical officer of Alpha Tau, discusses the alpha particle-emitting atom treatment and its ability to target cancer cells without harming healthy tissue.

Artificial Intelligence Dermatology Mobile Apps Present Critical Risks and Inconsistencies, JAMA Study Reports

AI mobile apps have critical gaps in efficacy, safety, and transparency, according to a new report.

Exploring the Link Between COVID-19 Research and Psoriatic Disease

We take a look at various studies exploring the relationship between psoriasis and COVID-19 vaccination, the link between COVID-19 and psoriasis severity, and more.

Exciting Exosomes in Aesthetic Dermatology

In her March edition of Cosmetic Conundrums, Zoe Diana Draelos, MD, explores the role of exosomes in aesthetic dermatology, changes in the skin, and more.

Consensus, Concern, and Commentary: Clinicians Share Thoughts on 'The BPO Bombshell'

We spoke with several dermatology experts to gauge their thoughts on Valisure's recent findings of benzene in benzoyl peroxide products--as well as what actions they plan to take moving forward.

Dietary Interventions May Serve as Worthwhile Adjunct Therapy in Patients With Vitiligo

While additional, larger studies are necessary, researchers said dietary choices may help reduce dependency on pharmacological methods.

Pointers With Portela: What is the Role of Vitamin A in Acne Treatment?

In this week’s Pointers With Portela, the 208SkinDoc dives into the efficacy and adverse effects of generic vitamin A to treat acne.

Skin Cancer and COVID-19: Research and Links Between Diagnosis and the Pandemic

We take a look at various studies examining the role of artificial intelligence in telemedicine photo quality, the impact of the COVID-19 pandemic and skin cancer diagnoses, and more.

AARS Responds to Valisure’s Data on Benzene in BPO Products

The statement said the petition came as a surprise to many ahead of AAD, and delves into the data complexity and patient considerations.

Experts Develop Evidence and Consensus-Based Recommendations for Diagnosing and Treating Vitiligo in Young Patients

The recommendations were recently published in JAMA Dermatology following an extensive literature review, article grading, and a review of research questions.

Rates, Incidence of Skin Cancer Found to be Higher in Patients With Skin of Color and in Rural Communities

Two posters at the AAD Annual Meeting examined disparities in skin cancer survival between urban and rural areas and assessed how having skin of color affects this.

Women's Dermatologic Society: New President Shares Hopes for Enduring Positive Change on Organization and Dermatology

Dermatology Times recently spoke with Latanya Benjamin, MD, FAAD, FAAP, the newly-appointed president of the WDS, to discuss her hopes and goals for her presidency.

Amlitelimab Demonstrates Sustained Improvements in Atopic Dermatitis Signs and Symptoms

Late-breaking data demonstrating the sustained improvements was presented at the American Academy of Dermatology Annual Meeting.

Assessing the Use of Telehealth in Dermatology After the COVID-19 Pandemic

Two recently published studies evaluated the uses of and attitudes toward telehealth in dermatology after the COVID-19 pandemic.

COVID-19 Impacts on Hair Loss, Pemphigus, Urticaria, and Rare Diseases

Explore recent research that shed light on potential associations and manifestations post-COVID-19 infection or vaccination.

Use of Virtual Reality in Dermatology Education Deemed Technically Feasible and Useful for Learning

Researchers developed a VR scenario skin cancer screening involving technical realization, curricular integration, and an evaluation of the subjective learning experience and teaching concept.

Kim Papp, MD, PhD, FRCPC: Exploring the Potential of ESK-001 in Plaque Psoriasis

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.

FDA Organizations Issue Joint Paper on Responsible and Ethical Use of Artificial Intelligence in Medical Research

The paper was authored and issued by the FDA Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, and Office of Combination Products.

UCB Receives Positive CHMP Opinion for Bimekizumab for Moderate to Severe HS

If approved, bimekizumab will be the first IL-17A and IL-17F inhibitor approved in Europe for hidradenitis suppurativa.